LSTA Lisata Therapeutics Inc

Price (delayed)

$1.67

Market cap

$15.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.86

Enterprise value

$2.15M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 30

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely ...

Highlights
The EPS has grown by 19% YoY and by 2.6% from the previous quarter
The net income has grown by 15% YoY
The gross profit has plunged by 83% YoY
The revenue has dropped by 83% year-on-year

Key stats

What are the main financial stats of LSTA

LSTA stock price

How has the Lisata Therapeutics stock price performed over time
Intraday
-21.23%
1 week
-53.55%
1 month
-51.45%
1 year
-37.22%
YTD
-10.22%
QTD
-50.88%

Financial performance

How have Lisata Therapeutics's revenue and profit performed over time
Revenue
$170,000
Gross profit
$170,000
Operating income
-$17.3M
Net income
-$16.35M
Gross margin
100%
Net margin
-9,618.2%
The gross profit has plunged by 83% YoY
The revenue has dropped by 83% year-on-year
LSTA's operating income is up by 20% year-on-year and by 5% since the previous quarter
The net income has grown by 15% YoY

Price vs fundamentals

How does LSTA's price correlate with its fundamentals

Growth

What is Lisata Therapeutics's growth rate over time

Valuation

What is Lisata Therapeutics stock price valuation
P/E
N/A
P/B
1.38
P/S
88.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.63
The EPS has grown by 19% YoY and by 2.6% from the previous quarter
LSTA's price to book (P/B) is 73% higher than its 5-year quarterly average of 0.8 but 27% lower than its last 4 quarters average of 1.9
LSTA's equity has plunged by 57% YoY and by 26% from the previous quarter
The revenue has dropped by 83% year-on-year
The stock's price to sales (P/S) is 13% less than its last 4 quarters average of 101.3

Efficiency

How efficient is Lisata Therapeutics business performance
LSTA's ROE has plunged by 67% YoY and by 21% from the previous quarter
Lisata Therapeutics's return on assets has shrunk by 56% YoY and by 17% QoQ
The ROS has grown by 4.6% from the previous quarter

Dividends

What is LSTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LSTA.

Financial health

How did Lisata Therapeutics financials performed over time
The company's total assets has shrunk by 51% YoY and by 21% QoQ
LSTA's current ratio is down by 44% YoY and by 27% QoQ
The debt is 100% less than the equity
LSTA's equity has plunged by 57% YoY and by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.